Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia
Key facts
- Who runs it
- Beijing Tongren Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 120 people enrolled
- Started
- 30 Jun 2023
- Ended
- 30 Jan 2026
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- soft peripheral defocus contact lenses
- Atropine 0.04%
- Atropine (0.01%)
- Single Vision Spectacles
- Record updated
- 12 February 2026
Who can take part
- Age
- 4 years to 16 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Mainland Chinese children aged 4-16 years at enrollment
- Spherical equivalent refraction ≤-6.0D in both eyes under cycloplegia
- Astigmatism ≤2.5D in both eyes
- Anisometropia ≤2.5D
- Best corrected visual acuity ≥0.1 logMAR in both eyes
- Subject-reported non-significant ocular and systemic medical history
- Ability and willingness to wear contact lenses (for intervention groups)
- Written informed consent from parents/guardians and assent from child
- Ability to attend all scheduled follow-up visits
Who cannot take part
- Previous use of myopia control treatments (atropine, orthokeratology, multifocal lenses) within 3 months
- Current use of systemic medications affecting pupil size or accommodation
- Current use of systemic medications that may significantly affect contact lens wear, tear film production, pupil size, adaptability, or refractive status
- Known allergies to atropine or contact lens materials
- Ocular diseases: strabismus, amblyopia, glaucoma, cataract, corneal disease
- Systemic diseases affecting ocular health
- History of ocular surgery or trauma
- Inability to perform study procedures
- Participation in other clinical trials within 2 months
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Peripheral contact lens in controlling myopia progression in high myopia children(PAM)is a prospective, single-center, randomized controlled trial with three parallel arms conducted at Beijing Tongren Hospital. Chinese children aged 6-12 years with high myopia (spherical equivalent ≤-6.0D) and annual progression ≥0.75D will be enrolled. Participants will be randomized 40:40:40 to: (1) combination therapy group receiving atropine 0.04% plus soft peripheral defocus contact lenses; (2) atropine monotherapy group receiving atropine 0.04% plus spectacles; or (3) control group receiving atropine 0.01% plus spectacles. The primary outcome is change in axial length and cycloplegic refraction at 24 months. Secondary outcomes include changes in pupil diameter, and safety parameters.
The 3 groups in the trial
- combination therapy groupTreatment being tested
40 patients in combination therapy group received atropine 0.04% plus soft peripheral defocus contact lenses
Treatment: soft peripheral defocus contact lenses and Atropine 0.04%
- atropine monotherapy groupTreatment being tested
40 patients in atropine monotherapy group received atropine 0.04% plus spectacles
Treatment: Atropine 0.04% and Single Vision Spectacles
- control groupPlacebo, for comparison
40 patients in control group received atropine 0.01% plus spectacles
Treatment: Atropine (0.01%) and Single Vision Spectacles
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Controlled Study of Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia
- Record updated
- 12 February 2026